Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
We investigate levels of IL-17 in serum and CSF in patients diagnosed at different stages of demyelinating diseases (RIS, CIS, relapsing remitting (RR) or active multiple sclerosis patients:AMS) as a marker of inflammatory condition.
J Neurol Sci. 2016 Sep 15;368:334-6. doi: 10.1016/j.jns.2016.07.052. Epub 2016 Jul 25.
Lien PubMed : https://www.ncbi.nlm.nih.gov/pubmed/27538659